Roundtable Discussion with Leading Experts
Jeff Nadler, MD, FACP
An expert faculty panel will be discussing recent advances in treatment including the role, uses and complications of newer antiretroviral drugs. The talk will include a discussion of benefits versus risks of using newer antiretroviral medicines early in the disease process. The purpose of this activity is to equip participants to make evidence-based decisions that incorporate the latest findings from clinical studies regarding efficacy and feasibility of newer antiretroviral agents. This round table discussion will provide participants with knowledge regarding treatment of HIV disease complications and co-morbid conditions. Discussion of difficult cases and atypical presentations will enlighten advanced HIV care providers. HIV experts will lead the discussion geared towards burning issues in HIV care. Recent national conferences and the results of significant trials will also be discussed.

Metabolic and Endocrine Disorders
Swati Modi, MD, AAHIVS
HIV and its medicines affect the metabolic and endocrine system in a variety of ways. This talk will focus on implications of HIV and antiretroviral therapy on burning metabolic and endocrine issues. Discussion will highlight HIV related insulin resistance, and various aspects of metabolic syndrome. Cardio-vascular diseases and dyslipidemia etiology and management in HIV positive patients will be addressed. The latest clinical studies and their findings on how HIV medicines can increase cardio-vascular events in HIV will be presented.
(Handouts)

HIV Issues of Aging – Cancer Management
Luis A. Espinoza, MD
The number of HIV infected patients who are older than 50 years of age continues to increase. This increase is not only the result of successful antiretroviral therapy but also of the newly diagnosed cases in this population. Several epidemiological studies have shown an increased incidence of non-AIDS-defining malignancies in this population. We will review the current cancer data in AIDS defining cancer and non-AIDS defining malignancies in this population, and the current prevention and screening methods.
(Handouts)

HIV and Substance Abuse
Thomas Freese, PhD
AIDS and substance abuse are overlapping epidemics. Risky sexual behavior under the influence of drugs, whether they are injected or taken by other methods, is one of the leading causes of HIV transmission. In the US, there are an estimated one million active injecting drug users and a similar number who use non-injection drugs or that abuse alcohol. We will discuss the current approaches to integrate prevention and treatment strategies in this population in order to decrease their risk for HIV transmission.
(Handouts)

HIV and Transplantation
Dushyantha Jayaweera, MD
Solid organ transplantation in selected HIV infected individuals is possible and with good results among kidney transplant recipients, and reasonable results among liver transplant recipients. This has been achieved with the ability to suppress viral replication with antiretroviral therapy and the improved ability to prevent and treat opportunistic infections. We will review the clinical strategies for transplantation in HIV infected recipients and the current management of these individuals.
(Handouts)

Sculptra®
Gerald Pierone, Jr., MD
Lipodystrophy is a recognized complication in HIV infection and it is likely multifactorial in origin. It may be related to side-effects from certain antiretrovirals, HIV itself, as well as genetic and other host factors. There will be a review of the pathogenesis and areas of intervention to prevent this complication and an update in the latest treatments. The loss of subcutaneous fat, lipoatrophy, will be reviewed together with the different strategies used to treat this complication.
(Handouts)